MedTrace Logo

Biomarker for Glycogen Storage Diseases (BioGlycogen)

NCT02385162 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-02-13

No results posted yet for this study

Summary

Development of a new MS-based biomarker for the early and sensitive diagnosis of Glycogen Storage Diseases from plasma. Testing for clinical robustness, specificity and long-term stability of the biomarker.

Conditions

  • Fructose Metabolism, Inborn Errors
  • Glycogen Storage Disease
  • Glycogen Storage Disease Type I
  • Glycogen Storage Disease Type II
  • Glycogen Storage Disease Type III
  • Glycogen Storage Disease Type IV
  • Glycogen Storage Disease Type V
  • Glycogen Storage Disease Type VI
  • Glycogen Storage Disease Type VII
  • Glycogen Storage Disease Type VIII

Sponsors & Collaborators

  • CENTOGENE GmbH Rostock

    lead INDUSTRY

Principal Investigators

  • Peter Bauer, Prof. · Centogene GmbH

Eligibility

Min Age
2 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-20
Primary Completion
2021-02-28
Completion
2021-02-28

Countries

  • Germany
  • India
  • Sri Lanka

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02385162 on ClinicalTrials.gov